-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Wins Multiple Prestigious Awards, Including a Place Among the Top 100 Manufacturing Enterprises in the Beijing-Tianjin-Hebei Region for 2025
Category:
发布时间：2025-11-14
【概要描述】
On November 13, the “2025 Beijing-Tianjin-Hebei Industrial Chain and Supply Chain Innovation Development Summit and Top 100 Enterprises High-Quality Development Conference,” co-hosted by the business federations of Beijing, Tianjin, and Hebei, was grandly held at the Taihang State Guest House in Shijiazhuang. Thanks to its outstanding overall strength and significant contributions to the industry, Shijiazhuang Sihua Pharmaceutical was honored with multiple accolades, including “Top 100 Manufacturing Enterprises in the Beijing-Tianjin-Hebei Region for 2025,” “Top 50 Innovative Leaders in Hebei’s Manufacturing Sector for 2025,” “Top 100 Manufacturing Enterprises in Hebei for 2025,” and “Top 100 Enterprises in Hebei for 2025,” ranking 112th, 7th, 56th, and 88th, respectively.
On November 13, the “2025 Beijing-Tianjin-Hebei Industrial Chain and Supply Chain Innovation Development Summit and Top 100 Enterprises High-Quality Development Conference,” co-hosted by the business federations of Beijing, Tianjin, and Hebei, was grandly held at the Taihang State Guest House in Shijiazhuang. Thanks to its outstanding overall strength and significant contributions to the industry, Shijiazhuang Sihua Pharmaceutical was honored with multiple accolades, including “Top 100 Manufacturing Enterprises in the Beijing-Tianjin-Hebei Region for 2025,” “Top 50 Innovative Leaders in Hebei’s Manufacturing Sector for 2025,” “Top 100 Manufacturing Enterprises in Hebei for 2025,” and “Top 100 Enterprises in Hebei for 2025,” ranking 112th, 7th, 56th, and 88th, respectively.
According to reports, this conference is themed “Taking Leading Enterprises as the Key Lever to Accelerate Collaborative Development of Industrial and Supply Chains in the Beijing–Tianjin–Hebei Region.” Its aim is to earnestly implement Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era, the spirit of the 20th National Congress of the Communist Party of China and the Second, Third, and Fourth Plenary Sessions of the 20th CPC Central Committee, as well as General Secretary Xi Jinping’s series of important instructions and directives; to speed up the implementation of the national strategy for coordinated development of the Beijing–Tianjin–Hebei region; to fully leverage the advantages of leading enterprises as critical nodes and dominant players in industrial and supply chains; and to accelerate innovative, collaborative development of these chains across the three regions. The Top 100 list unveiled at this event was compiled by the enterprise federations of Beijing, Tianjin, and Hebei, following a rigorous scientific selection process modeled on the authoritative “China Top 500 Enterprises” ranking. It serves as a crucial benchmark for assessing the core competitiveness of regional enterprises and for gaining insight into the evolving trends of industry.
In recent years, the Group has remained firmly committed to high-quality development as its top priority, focusing on key elements such as R&D, marketing, quality, and manufacturing. It has vigorously implemented an innovation-driven strategy, relentlessly pursuing innovation with a sense of urgency and momentum, and continuously promoting the deep integration and coordinated development of the innovation chain, talent chain, industrial chain, and supply chain. The Group is accelerating the establishment of a modern industrial system that is led by innovative drugs, underpinned by specialty chemical pharmaceutical preparations and active pharmaceutical ingredients, and extended by high-end pharmaceutical packaging materials and specialized biologics, thereby continuously fostering and developing new drivers of productivity. Meanwhile, technological innovation and digital transformation have powerfully enabled the integrated development of “APIs plus formulations.” The Group consistently ranks among the industry leaders in the number of applications submitted and approvals obtained, with a cumulative total of 156 drug varieties and 207 dosage forms having either passed or been deemed to have passed the evaluation of generic drug quality and therapeutic equivalence. These significant innovation achievements have markedly improved product accessibility, driving a new leap in the Company’s innovation influence and market competitiveness.
“At this pivotal juncture—marking the conclusion of the 14th Five-Year Plan and the commencement of the 15th—the Group has been proudly recognized on the 2025 Top 100 Enterprises list for the Beijing–Tianjin–Hebei region and Hebei Province, injecting strong new momentum into the enterprise’s high-quality development. This honor fully underscores the Group’s proactive role in driving regional industrial upgrading and leading innovation in the biopharmaceutical sector,” said a Group executive. “Going forward, we will remain firmly rooted in Hebei, implementing more pragmatic initiatives to deepen our engagement in the dynamic Beijing–Tianjin–Hebei development corridor. Leveraging technological innovation and supply-chain optimization, we will continue to contribute the strength of Shijiazhuang Sihua Pharmaceutical Group to the region’s high-quality economic growth.”
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091